Zetagen Therapeutics is dedicated to developing innovative bone growth products using a unique molecular pathway. The company focuses on commercializing a small molecule-based osteoinductive platform technology to treat bone-related injuries and conditions. Their market focus includes therapies for metastatic and primary cancers, with a particular emphasis on bone metastases and cervical degenerative disc disease.
Zetagen Therapeutics has achieved significant milestones, including the approval to begin a pilot study of their ZetaFuse® Bone Graft in Australia. The company has also appointed notable experts like Debasish (Debu) Tripathy, M.D., to its advisory board. Their local therapy for treating bone metastases in breast cancer patients has shown promising results, such as decreased pain and fracture prevention, underscoring their impact in the field of bone health and cancer treatment.
